Chengyuan Liang

Dr. Chengyuan Liang holds a BA in Pharmaceutical Engineering and a PhD in Medicinal Chemistry, both from China Pharmaceutical University. He also worked as a visiting scholar at the Department of Chemistry, Georgia State University, USA from 2016 o 2017. Currently, he is a full professor in the Department of Medicinal Chemistry at Shaanxi University of Science & Technology. Dr. Liang's research interests are focused on developing novel therapeutics such as inhibitors, PROTACs, and ADCs, using chemistry-driven drug discovery. These therapeutics are aimed at treating infectious diseases caused by viral infections (such as Coronavirus and influenza) and resistant pathogens, including multidrug-resistant bacteria and resistant mycoplasma. He has contributed to several book chapters published by Elsevier and Springer Nature on drug discovery, and has published over 60 peer-reviewed journal articles in international high-impact peer-reviewed journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, and Phytomedicine. His total citations exceed 1300, and he has been granted 120 patents in China, USA, and Japan. Dr. Liang is also the director of the Xi’an Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research and Shaanxi Provincial University Engineering Research Center for Therapeutic Drugs for Major Infectious Diseases.